China Resources Double-Crane Pharmaceutical (SHA:600062) subsidiary Double Crane Limin obtained the approval for the quality and efficacy consistency evaluation of its famotidine injection from China's medical products administrator.
Famotidine is suitable for upper gastrointestinal bleeding caused by ulcers, according to a Jan. 4 filing with the Shanghai bourse.
Shares of the pharmaceutical company closed 3% higher Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.